Beyond viral and TP53-related alterations, emerging genomic changes such as Loss of Y chromosome (LOY) have recently been implicated in urological cancers, including prostate and bladder cancer, where they are associated with immune dysregulation and adverse outcomes. Here, TP53 is linked to urinary bladder cancer.